S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
S&P 500   3,465.39 (+0.34%)
DOW   28,335.57 (-0.10%)
QQQ   284.74 (+0.20%)
AAPL   115.04 (-0.61%)
MSFT   216.23 (+0.62%)
FB   284.79 (+2.40%)
GOOGL   1,632.98 (+1.64%)
AMZN   3,204.40 (+0.88%)
TSLA   420.63 (-1.21%)
NVDA   543.61 (+1.72%)
BABA   309.92 (+1.19%)
CGC   19.73 (-2.81%)
GE   7.63 (-1.17%)
MU   52.85 (-2.81%)
AMD   81.96 (+3.20%)
T   27.82 (-1.63%)
F   8.16 (-0.61%)
ACB   4.68 (-3.51%)
GILD   60.79 (+0.20%)
NFLX   488.28 (+0.63%)
BA   167.36 (-1.01%)
NIO   27.16 (-0.80%)
DIS   128.35 (+0.62%)
Log in
NASDAQ:AMED

Amedisys Stock Forecast, Price & News

$251.11
+2.29 (+0.92 %)
(As of 10/23/2020 04:30 PM ET)
Add
Compare
Today's Range
$245.78
Now: $251.11
$253.56
50-Day Range
$224.06
MA: $238.30
$253.44
52-Week Range
$127.12
Now: $251.11
$258.62
Volume92,859 shs
Average Volume279,860 shs
Market Capitalization$8.15 billion
P/E Ratio65.05
Dividend YieldN/A
Beta0.9
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, or cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 18, 2020, the company owned and operated 479 care centers in 38 states and the District of Columbia. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Read More
Amedisys logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031
Employees21,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.96 billion
Cash Flow$6.34 per share
Book Value$19.89 per share

Profitability

Net Income$126.83 million

Miscellaneous

Market Cap$8.15 billion
Next Earnings Date10/28/2020 (Confirmed)
OptionableOptionable
$251.11
+2.29 (+0.92 %)
(As of 10/23/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amedisys (NASDAQ:AMED) Frequently Asked Questions

How has Amedisys' stock been impacted by COVID-19 (Coronavirus)?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMED stock has increased by 47.3% and is now trading at $251.11.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Amedisys?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amedisys
.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Amedisys
.

How can I listen to Amedisys' earnings call?

Amedisys will be holding an earnings conference call on Wednesday, October 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) posted its earnings results on Tuesday, July, 28th. The health services provider reported $1.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.53. The health services provider earned $485.06 million during the quarter, compared to analyst estimates of $468.38 million. Amedisys had a return on equity of 22.41% and a net margin of 6.50%. Amedisys's revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the business posted $1.21 earnings per share.
View Amedisys' earnings history
.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys issued an update on its FY20 earnings guidance on Tuesday, July, 28th. The company provided earnings per share (EPS) guidance of $4.84-5.06 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.54. The company issued revenue guidance of $2.04-2.07 billion, compared to the consensus revenue estimate of $2.03 billion.

What price target have analysts set for AMED?

14 analysts have issued 1 year price targets for Amedisys' stock. Their forecasts range from $160.00 to $290.00. On average, they anticipate Amedisys' share price to reach $239.43 in the next twelve months. This suggests that the stock has a possible downside of 4.7%.
View analysts' price targets for Amedisys
.

Are investors shorting Amedisys?

Amedisys saw a decline in short interest in September. As of September 15th, there was short interest totaling 420,900 shares, a decline of 32.4% from the August 31st total of 623,000 shares. Based on an average daily trading volume, of 288,800 shares, the short-interest ratio is presently 1.5 days. Currently, 1.3% of the company's stock are short sold.
View Amedisys' Short Interest
.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Who are Amedisys' key executives?

Amedisys' management team includes the following people:
  • Mr. Paul Berthold Kusserow, Chairman, Pres & CEO (Age 59, Pay $1.33M)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 51, Pay $1.22M)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 53, Pay $1.34M)
  • Mr. David L. Kemmerly, Chief Legal & Gov. Affairs Officer (Age 57, Pay $851.77k)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 53, Pay $844.58k)
  • Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems
  • Mr. Michael P. North, Chief Information Officer (Age 55)
  • Mr. Denise Bohnert, Chief Compliance Officer (Age 42)
  • Kendra Kimmons, VP of Marketing & Communications
  • Mr. John Nugent, Chief Acquisitions Officer

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (2.14%), Assenagon Asset Management S.A. (0.61%), Standard Life Aberdeen plc (0.57%), Retirement Systems of Alabama (0.25%), Envestnet Asset Management Inc. (0.15%) and Gradient Investments LLC (0.06%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys
.

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Gradient Investments LLC, HBW Advisory Services LLC, and State of Alaska Department of Revenue. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys
.

Which major investors are buying Amedisys stock?

AMED stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Standard Life Aberdeen plc, Riverbridge Partners LLC, Pacer Advisors Inc., Envestnet Asset Management Inc., USA Financial Portformulas Corp, Icon Wealth Partners LLC, and Vivid Financial Management Inc.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys
.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $251.11.

How big of a company is Amedisys?

Amedisys has a market capitalization of $8.15 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,000 workers across the globe.

What is Amedisys' official website?

The official website for Amedisys is www.amedisys.com.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]

This page was last updated on 10/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.